Azafaros
Azafaros develops therapeutic agents for rare metabolic disorders, specifically lysosomal storage disorders.
$150M Series B+ ·
Led by Forbion Capital Partners · Source: startupintros.com
Total raised: $177M across 2 sourced rounds
All 2 rounds ↓Signals
About Azafaros
It focuses on an orally available azasugar, nizubaglustat, designed to treat the central nervous system and interfere with glycosphingolipid metabolism. Azafaros licenses these agents.
Azafaros | 655 days from website to first raise on record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $150M | startupintros.com | ||
| Series A | $27M | startupintros.com |
Timeline
- Website created
Founders and team
- OMOlivier Morand Founder
AS
Amy Sullivan Chief Financial OfficerSP
Stefano Portolano Chief Executive Officer
Investors
BBioGeneration Ventures
BBioMedPartners
FForbion Capital Partnerslead investor
JJeito Capitallead investor
PPictet Alternative Advisors
SSchroders Capital
SSeroba Life Sciences
Companies like Azafaros
NNoema PharmaSeries B+ · Nov 2025
HHolobiomeSeed · Jul 2026
RReRx
EEmalex Biosciences$250M Series B+ · Nov 2022
BBloom Science$12M Series A · Dec 2021
SStarlight TherapeuticsSeed · Apr 2026
Other companies backed by Forbion Capital Partners
OOMass Therapeutics$310M Series B+ · Oct 2026
KKynexis$112.57M Series A · Aug 2026
RRQ Bio$115M Series A · Jun 2026
CCellCentric$220M Series B+ · May 2026
TTropic Biosciences$105M Series B+ · Mar 2026
SSidera Bio$109.99M Series A · Nov 2025
Forbion Capital Partners portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/azafaros (get a free API key).